1
|
Baert L, Manfroi B, Quintero M, Chavarria O, Barbon PV, Clement E, Zeller A, Van Kuppevelt T, Sturm N, Moreaux J, Tveita A, Bogen B, McKee T, Huard B. 3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness. Matrix Biol 2023; 120:60-75. [PMID: 37201729 DOI: 10.1016/j.matbio.2023.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 05/12/2023] [Accepted: 05/15/2023] [Indexed: 05/20/2023]
Abstract
Multiple myeloma is a hematological neoplasm derived from plasma cells invariably developing in the bone marrow (BM). The persisting clinical challenge in MM resides in its high ability to resist drugs as shown by the frequent relapses observed in patients regardless of the treatment applied. In a mouse model of MM, we identified a subpopulation of cells harboring increased resistance to current MM drugs. These cells bound a proliferation inducing ligand (APRIL), a key MM promoting/survival factor. APRIL binding involved the heparan sulfate (HS) chain present on syndecan-1 (SDC-1), and correlated with reactivity to the anti-HS antibody 10e4. 10e4+cells had a high proliferation activity, and were able to form colonies in 3-D cultures. 10e4+ cells were the only cells able to develop in BM after intravenous injection. They also resisted drugs in vivo, since their number increased after treatment in BM. Notably, 10e4+ cells differentiated into 10e4- cells upon in vitro and in vivo expansion. Expression of one sulfotransferase, HS3ST3a1, allowed modification of syndecan-1 to confer reactivity to 10e4 and binding to APRIL. HS3ST3a1 deletion inhibited tumorigenesis in BM. Notably, the two populations coexisted at a variable frequency in the BM of MM patients at diagnosis. In total, our results indicate that 3-O-sulfation on SDC-1 carried out by HS3ST3a1 defines aggressive MM cells, and that targeting of this enzyme could possibly be used to better control drug resistance.
Collapse
Affiliation(s)
- L Baert
- Institute for Advanced Biosciences, University Grenoble-Alpes, INSERM U1209, La Tronche, France
| | - B Manfroi
- Institute for Advanced Biosciences, University Grenoble-Alpes, INSERM U1209, La Tronche, France
| | - M Quintero
- translational innovation in medicine and complexity, University Grenoble-Alpes, CNRS UMR5525, La Tronche, France
| | - O Chavarria
- Institute for Advanced Biosciences, University Grenoble-Alpes, INSERM U1209, La Tronche, France
| | - P V Barbon
- Institute for Advanced Biosciences, University Grenoble-Alpes, INSERM U1209, La Tronche, France
| | - E Clement
- translational innovation in medicine and complexity, University Grenoble-Alpes, CNRS UMR5525, La Tronche, France
| | - A Zeller
- Department of Pathology and Immunology, university Hospitals, Geneva, Switzerland
| | - T Van Kuppevelt
- Rabdoud university medical center, Nijmegen, the Netherlands
| | - N Sturm
- translational innovation in medicine and complexity, University Grenoble-Alpes, CNRS UMR5525, La Tronche, France; Department of Pathology, university Hospital, Grenoble, France
| | - J Moreaux
- Department of Biological Hematology, University Hospital, Montpellier, France; Institute of Human Genetics, centre national de la recherche scientifique, University Montpellier, France
| | - A Tveita
- Department of Immunology and transfusion medicine, Institute for Immunology, university Hospital, Oslo, Norway
| | - B Bogen
- Department of Immunology and transfusion medicine, Institute for Immunology, university Hospital, Oslo, Norway; University of Oslo, Norway
| | - T McKee
- Department of clinical pathology, university Hospitals, Geneva, Switzerland
| | - B Huard
- translational innovation in medicine and complexity, University Grenoble-Alpes, CNRS UMR5525, La Tronche, France.
| |
Collapse
|
2
|
Wang D, Fløisand Y, Myklebust CV, Bürgler S, Parente-Ribes A, Hofgaard PO, Bogen B, Taskén K, Tjønnfjord GE, Schjesvold F, Dalgaard J, Tveita A, Munthe LA. Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice. Leukemia 2017; 31:2114-2121. [PMID: 28232741 DOI: 10.1038/leu.2017.69] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Revised: 02/03/2017] [Accepted: 02/14/2017] [Indexed: 02/06/2023]
Abstract
Multiple myeloma (MM) is a plasma cell malignancy where MM cell growth is supported by the bone marrow (BM) microenvironment with poorly defined cellular and molecular mechanisms. MM cells express CD40, a receptor known to activate autocrine secretion of cytokines and elicit proliferation. Activated T helper (Th) cells express CD40 ligand (CD40L) and BM Th cells are significantly increased in MM patients. We hypothesized that activated BM Th cells could support MM cell growth. We here found that activated autologous BM Th cells supported MM cell growth in a contact- and CD40L-dependent manner in vitro. MM cells had retained the ability to activate Th cells that reciprocated and stimulated MM cell proliferation. Autologous BM Th cells supported MM cell growth in xenografted mice and were found in close contact with MM cells. MM cells secreted chemokines that attracted Th cells, secretion was augmented by CD40-stimulation. Within 14 days of culture of whole BM aspirates in autologous serum, MM cells and Th cells mutually stimulated each other, and MM cells required Th cells for further expansion in vitro and in mice. The results suggest that Th cells may support the expansion of MM cells in patients.
Collapse
Affiliation(s)
- D Wang
- Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Y Fløisand
- Department of Haematology, Oslo University Hospital, Oslo, Norway
| | - C V Myklebust
- Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - S Bürgler
- Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.,Department of Haematology, Oslo University Hospital, Oslo, Norway
| | - A Parente-Ribes
- Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - P O Hofgaard
- Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.,KG Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - B Bogen
- Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.,KG Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - K Taskén
- Centre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo, Norway
| | - G E Tjønnfjord
- Department of Haematology, Oslo University Hospital, Oslo, Norway.,Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - F Schjesvold
- Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.,Department of Haematology, Oslo University Hospital, Oslo, Norway
| | - J Dalgaard
- Department of Haematology, Oslo University Hospital, Oslo, Norway.,Department of Medicine, Vestre Viken Trust, Drammen Hospital, Drammen, Norway
| | - A Tveita
- Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - L A Munthe
- Department of Immunology, Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| |
Collapse
|
3
|
Haabeth OA, Tveita A, Fauskanger M, Hennig K, Hofgaard PO, Bogen B. Idiotype-specific CD4(+) T cells eradicate disseminated myeloma. Leukemia 2015; 30:1216-20. [PMID: 26449664 DOI: 10.1038/leu.2015.278] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- O A Haabeth
- Centre for Immune Regulation, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway
| | - A Tveita
- Centre for Immune Regulation, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway
| | - M Fauskanger
- Centre for Immune Regulation, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway
| | - K Hennig
- Centre for Immune Regulation, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway
| | - P O Hofgaard
- KG Jebsen Centre for Influenza Vaccine Research, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway
| | - B Bogen
- Centre for Immune Regulation, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.,KG Jebsen Centre for Influenza Vaccine Research, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway
| |
Collapse
|